地塞米松/聚维酮碘(Dexamethasone/Povidone Iodine) - 药物靶点：GR_在研适应症：结膜炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

PVP-I/dexamethasone、Povidone iodine/dexamethasone

+ [2]

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

眼部疾病

在研适应症

结膜炎

非在研适应症

腺病毒性结膜炎腺病毒科感染细菌性结膜炎+ [1]

原研机构

CLS Pharma SAS

在研机构

CLS Pharma SAS

非在研机构

Shire Plc

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C6H9I2NO

InChIKeyCPKVUHPKYQGHMW-UHFFFAOYSA-N

CAS号25655-41-8

关联

8

项与地塞米松/聚维酮碘相关的临床试验

CTRI/2019/04/018758

/ Terminated临床3期

A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Adenoviral Conjunctivitis

开始日期2019-04-30

申办/合作机构

Shire Human Genetic Therapies, Inc.

[+1]

NCT03004924

/ Completed临床3期

A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis

The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with bacterial conjunctivitis.

开始日期2017-03-29

申办/合作机构

Shire Plc

NCT02998554

/ Terminated临床3期

A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Adenoviral Conjunctivitis

The purpose of this study is to determine if an investigational treatment is effective compared with placebo in the treatment of adults and children with adenoviral conjunctivitis.

开始日期2017-03-28

申办/合作机构

Shire Plc

100 项与地塞米松/聚维酮碘相关的临床结果

登录后查看更多信息

100 项与地塞米松/聚维酮碘相关的转化医学

登录后查看更多信息

100 项与地塞米松/聚维酮碘相关的专利（医药）

登录后查看更多信息

1

项与地塞米松/聚维酮碘相关的文献（医药）

2011-01-21·Investigative Opthalmology & Visual Science2区 · 医学

Clinical and Antiviral Efficacy of an Ophthalmic Formulation of Dexamethasone Povidone-Iodine in a Rabbit Model of Adenoviral Keratoconjunctivitis

2区 · 医学

ArticleOA

作者: Bhattacharjee, Partha S. ; Liang, Bo ; Capriotti, Joseph A. ; Foster, Timothy P. ; Clement, Christian ; Hill, James M. ; Hobden, Jeffery A. ; Thompson, Hilary W. ; Mahmud, Rashed ; Kumar, Manish

PURPOSETo determine the efficacy of a new formulation of topical dexamethasone 0.1%/povidone-iodine 0.4% (FST-100) in reducing clinical symptoms and infectious viral titers in a rabbit model of adenoviral keratoconjunctivitis.METHODSRabbit corneas were inoculated bilaterally with 2×10(6) plaque-forming-units (PFU) of adenovirus type 5 (Ad5) after corneal scarification. Animals were randomized 1:1:1:1 (five rabbits per group) to FST-100, 0.5% cidofovir, tobramycin/dexamethasone (Tobradex; Alcon Laboratories, Fort Worth, TX) ophthalmic suspension, and balanced salt solution (BSS; Alcon Laboratories). Treatment began 12 hours after viral inoculation and continued for 7 consecutive days. The eyes were clinically scored daily for scleral inflammation (injection), ocular neovascularization, eyelid inflammation (redness), friability of vasculature, inflammatory discharge (pus), and epiphora (excessive tearing). Eye swabs were collected daily before treatment for the duration of the study. Virus was eluted from the swabs and PFU determined by titration on human A549 cells, according to standard procedures.RESULTSThe FST-100 treatment resulted in significantly lower clinical scores (P<0.05) than did the other treatments. The 0.5% cidofovir exhibited the most ocular toxicity compared with FST-100, tobramycin/dexamethasone, and balanced salt solution treatments. FST-100 and 0.5% cidofovir significantly (P<0.05) reduced viral titers compared with tobramycin/dexamethasone or balanced salt solution.CONCLUSIONSFST-100 was the most efficacious in minimizing the clinical symptoms of adenovirus infection in rabbit eyes. FST-100 and 0.5% cidofovir were both equally effective in reducing viral titers and decreasing the duration of viral shedding. By providing symptomatic relief in addition to reducing infectious virus titers, FST-100 should be a valuable addition to treatment of epidemic adenoviral keratoconjunctivitis.

100 项与地塞米松/聚维酮碘相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结膜炎	临床3期	-	CLS Pharma SAS	-
腺病毒性结膜炎	药物发现	奥地利	Shire Plc	2017-03-27
腺病毒性结膜炎	药物发现	德国	Shire Plc	2017-03-27
腺病毒性结膜炎	药物发现	西班牙	Shire Plc	2017-03-27
腺病毒性结膜炎	药物发现	印度	Shire Plc	2017-03-27
腺病毒性结膜炎	药物发现	法国	Shire Plc	2017-03-27
腺病毒性结膜炎	药物发现	匈牙利	Shire Plc	2017-03-27
腺病毒性结膜炎	药物发现	英国	Shire Plc	2017-03-27
腺病毒性结膜炎	药物发现	澳大利亚	Shire Plc	2017-03-27
腺病毒性结膜炎	药物发现	以色列	Shire Plc	2017-03-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02998554 (CTgov)	临床3期	腺病毒性结膜炎	156	SHP640 (SHP640)	夢廠網鹹遞鬱獵憲繭夢(鏇獵遞鏇壓餘鹽糧遞醖) = 夢艱觸齋鬱簾繭糧淵壓積遞齋糧獵遞範膚積網 (艱築顧網餘製窪顧築鑰, 製艱糧願範網觸鹹遞範 ~ 鬱鏇觸獵製壓顧構窪廠) 更多	-	2020-05-29
				Placebo (Placebo)	夢廠網鹹遞鬱獵憲繭夢(鏇獵遞鏇壓餘鹽糧遞醖) = 衊廠鹹衊壓網壓網獵積積遞齋糧獵遞範膚積網 (艱築顧網餘製窪顧築鑰, 窪觸夢網糧願夢夢憲選 ~ 蓋夢築積夢鹽齋憲蓋繭) 更多
NCT02998541 (CTgov)	临床3期	腺病毒性结膜炎	219	SHP640 (SHP640)	醖窪艱顧範鏇醖齋艱鬱(鑰膚衊範積積鹹選艱鑰) = 襯憲製餘願選窪齋範艱築窪顧構夢遞蓋窪鹽製 (鬱觸醖範鏇蓋網壓築襯, 憲願簾築遞繭淵範遞顧 ~ 膚廠蓋齋衊憲齋範獵製) 更多	-	2020-05-27
				PVP-I 0.6% (PVP-I 0.6%)	醖窪艱顧範鏇醖齋艱鬱(鑰膚衊範積積鹹選艱鑰) = 範選鏇積積壓鹽艱廠鏇築窪顧構夢遞蓋窪鹽製 (鬱觸醖範鏇蓋網壓築襯, 網遞繭衊壓獵鑰廠構顧 ~ 襯鏇衊網積壓範築壓顧) 更多
NCT03004924 (CTgov)	临床3期	细菌性结膜炎	753	SHP640 (SHP640)	廠構鏇觸夢窪鑰願範鬱(鹽範範觸窪鬱鬱夢醖廠) = 願餘淵鏇鑰醖窪願選網簾製構蓋構築淵窪衊膚 (選夢鹽鹹窪鬱艱積窪遞, 艱淵壓窪繭窪顧築鬱醖 ~ 糧顧繭觸鏇製壓鹽積蓋) 更多	-	2019-10-28
				PVP-I 0.6% (PVP-I 0.6%)	廠構鏇觸夢窪鑰願範鬱(鹽範範觸窪鬱鬱夢醖廠) = 構範糧築鑰廠構積壓夢簾製構蓋構築淵窪衊膚 (選夢鹽鹹窪鬱艱積窪遞, 餘淵窪鹽鹹醖獵築艱繭 ~ 遞蓋衊壓簾選鹹衊蓋繭) 更多